- Trial phase
- Approved
- Time to market
- Approved, marketed in the U.S. since July 31, 2009
- Why 3/10
- No hard, dated binary catalyst exists for this molecule in the next ~12 months: INVEGA SUSTENNA was FDA-approved on 2009-07-31, it is already fully commercialized, and there is no pending PDUFA, pivotal readout, or label-expansion decision for it, so per the rubric the score is capped in the 3-5 band and set at 3 because it is one mature product inside a diversified mega-cap (JNJ) where it can drive no concentrated move.
For a JNJ investor, INVEGA SUSTENNA is a mature, likely-eroding cash-flow product inside a diversified healthcare giant, not a catalyst to trade. Watch quarterly J&J earnings (pharma segment Invega franchise sales) and any FDA action on generic or biosimilar long-acting injectable paliperidone for erosion signals; a decisive bull/bear case on JNJ should be built on its oncology/immunology pipeline (e.g., RYBREVANT) and medtech, not this 2009-vintage antipsychotic.
Price Chart
Executive Summary
INVEGA SUSTENNA is Johnson & Johnson's long-acting injectable atypical antipsychotic (paliperidone palmitate), FDA-approved since July 31, 2009 and one of a family of Invega products. As an approved, mature product inside a $262 mega-cap with a 22-analyst buy-rated consensus, the drug carries no pending regulatory binary and is best read as a slow-erosion cash-flow asset (generic oral paliperidone already exists, ANI Pharmaceuticals' ANDA204452, and FDA label updates continued through 2026) rather than a share-price catalyst.
How It Works
Paliperidone is an atypical antipsychotic (per FDA's own drug classification) used mainly to treat schizophrenia. INVEGA SUSTENNA is the long-acting injectable version: instead of a daily pill, the drug is injected and releases slowly from the injection site over weeks, which helps patients who struggle to take daily medication. Antipsychotics work by dampening overactive dopamine/serotonin signaling in the brain that drives hallucinations and delusions.
Trial Status
Fully approved and commercialized: SecBot's catalyst records show INVEGA SUSTENNA (paliperidone palmitate) received FDA approval on 2009-07-31, joining the Invega family of J&J products (oral INVEGA approvals 2006-12-19 and 2007-04-27, and INVEGA HAFYERA approval 2015-05-18). No company-sponsored Phase 2/3 paliperidone trials appear in SecBot's pipeline data, only academic studies. The regulatory story today is class-level: FDA safety-labeling actions across paliperidone products in 2026 (boxed warning on increased mortality in elderly dementia-related psychosis) apply to the oral generic products of ANI Pharmaceuticals and Bryant Ranch Prepack.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for INVEGA SUSTENNA specifically (no PDUFA/readout in the next ~12 months).
- Company-level: quarterly J&J earnings where Invega franchise sales are reported (latest 8-K/10-Q filings).
- Watch for FDA label/approval actions on any generic or biosimilar paliperidone palmitate long-acting injectable.
- Class-wide paliperidone safety-labeling updates, which continued through mid-2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report